The International Journal of Neuropsychopharmacology
September 1, 2026
S Makhoul, N Abdulameer
Abstract Background Esketamine intranasal spray is FDA-approved for treatment-resistant depression (TRD), but it is not licensed for use in bipolar disorder due to the risk of antidepressants inducing manic or hypomanic episodes. To date, there is limited data on the use of intranasal esketamine in bipolar disorder, and no previous reports of using esketamine as an add-on treatment in patients...
International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background Antidepressant effects of ketamine and esketamine are short lived, often lasting only weeks after multiple treatments. With that in mind, it has been considered addition of psychotherapy may enhance outcomes. One approach, knows as Ketamine Assisted Psychotherapy (KAP) focuses on "integration " of the dissociative experience induced by ketamine, and suggests this may produce...
The Brown University Psychopharmacology Update
September 1, 2026
A systematic review and meta‐analysis encompassing 26 ran‐domized controlled trials (RCTs) has concluded that both single and repeated infusions of ketamine significantly improve suicidality and depressive symptoms in patients with a major depressive episode. Most of the serious adverse events that were reported in the included trials were determined to be unrelated to study treatment.
Medical Science
August 30, 2026
Julia Rogała, Kinga Polityńska, Dominika Ruszel et al.
Treatment-resistant depression occurs in roughly one-third of individuals diagnosed with depression.Ketamine and esketamine have appeared as innovative antidepressant treatments that target the glutamatergic system and deliver promising therapeutic options for patients unresponsive to conventional monoaminergic antidepressants.This review delivers a complete analysis of the mechanisms of...
Bipolar Disorders
August 30, 2026
Chih‐Cheng Lin, Lien‐chung Wei
OBJECTIVES: To contextualize the real-world findings of repeated intravenous ketamine infusions for treatment-resistant bipolar depression (TRBPD) and identify priorities for safer, more durable clinical implementation. METHODS: We provide a focused commentary on Zhou et al. (2023) and integrate selected evidence concerning inflammatory and metabolic correlates, neurocognitive outcomes, and...
Eur Arch Psychiatry Clin Neurosci
August 29, 2026
Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.
Eur Neuropsychopharmacol
August 27, 2026
correction
Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].
BMC Anesthesiology
August 26, 2026
Mao Li, Wen Wen, Xiang Wen
Postoperative depression and anxiety are common in elderly patients undergoing joint replacement surgery and may affect recovery. Esketamine has rapid antidepressant effects, but evidence for combined perioperative use remains limited, particularly in elderly patients undergoing joint replacement surgery. This study evaluated the association between combined perioperative esketamine exposure...
Healthcare
August 26, 2026
Mostafa A. Sayed Ali, Palanisamy Amirthalingam, Hanan Alshareef et al.
Background/Objectives: This study evaluated the real-world effectiveness and safety of intranasal esketamine plus oral antidepressants compared with venlafaxine-based oral antidepressant therapy in adults with moderate-to-severe treatment-resistant depression (TRD). Methods: This retrospective cohort study used electronic medical records from a mental health hospital between January 2023 and...
Neuropsychiatrie
August 25, 2026
Nicolas Schmelzle, Katrin Neubacher, Paul L. Plener et al.
BACKGROUND: Depressive symptoms and suicidality are highly prevalent in adolescents with early-onset psychosis (EOP) and often remain refractory to standard treatment. While S‑ketamine is an established treatment for treatment-resistant depression in adults (TRD), its use in primary psychotic disorders remains scarce due to risk of exacerbation of psychotic symptoms. CASE PRESENTATION: We...